OAMG
NVCR icon

Odey Asset Management Group’s NovoCure NVCR Stock Holding History

Odey Asset Management Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50,000
Closed -$2.41M – 63
2019
Q1 		$2.41M Buy
+50,000
New +$2.41M 0.2% 42

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Odey Asset Management Group's NVCR Position: Q2 2019 in Review

Odey Asset Management Group sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 50,000 shares — an estimated $2.41M sold.

Odey Asset Management Group first reported a position in NVCR in Q1 2019 and held it in 1 quarter. The position peaked at $2.41M in Q1 2019. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

  • Odey Asset Management Group reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
  • Odey Asset Management Group sold 50,000 NovoCure shares in Q2 2019, an estimated $2.41M.
  • Odey Asset Management Group first reported a position in NovoCure in Q1 2019 and held it in 1 quarter.
  • Odey Asset Management Group's NovoCure position peaked at $2.41M in Q1 2019.
  • 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Odey Asset Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.